Safety and activitity of immune checkpoint inhibitors for cancer in people living with HIV

There is a paucity of data on the use of immune checkpoint inhibitors (ICIs) for malignancies in people living with HIV (PWH). A multinational real-world retrospective study included PWH who received ICIs while on antiretroviral therapy (ART). ICIs were deemed safe and had differential activity across tumor types. Among PWH with NSCLC, clinical outcomes were not generally influenced by CD4+ T-cell counts or ART regimens. In a subset of PWH with metastatic NSCLC, safety and activity of ICIs were comparable with safety and activity in a matched cohort of people living without HIV after matching for relevant clinical variables.